Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | TET3 | O43151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839524 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL6839428 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL3776280 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL3781040 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL6838462 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL13062508 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL14643178 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL13015306 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL640339 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 | |
| SCHEMBL3776284 | 1.00 | OR51E2 (0.57) | OR51E2PDE4AUSP2SLCO1B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | claimed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20230077014-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC | 2021-11-25 | — | — | US | claimed |
| WO-2021158714-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158574-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| JP-59136488-A | — | — | None | — | — | JP | disclosed |
| US-12391807-B2 | Extraction of valuable components from bark | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) | 2025-08-19 | — | — | US | disclosed |
| US-20250223392-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC (CH) | 2025-07-10 | — | — | US | disclosed |
| US-12286501-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2025-04-29 | — | — | US | disclosed |
| CN-116326614-B | Flour improver or flour product improver and application thereof | 丰益(上海)生物技术研发中心有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2017040844-A1 | TOPICAL ANTIVIRAL COMPOSITIONS | TOPICAL REMEDY, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3049473-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015042711-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE, INC. (CA) | 2015-04-02 | — | — | WO | disclosed |
| US-5726045-A | EXPOSING CANONICAL DNA TO AN ISOLATED AND SUBSTANTIALLY PURE ENZYME WHICH CATALYZES THE CONVERSION OF DNA TO CO-DNA | KAGAWA HARUO (JP) | 1998-03-10 | — | — | US | disclosed |
| WO-1997020919-A1 | MATERIALS AND METHODS FOR CONVERTING DNA TO CO-DNA | KAGAWA HARUO (JP) | 1997-06-12 | — | — | WO | disclosed |
| JP-S59136488-A | PREPARATION OF 2-DEOXY-D-ERYTHRO-PENTOSE | NOGUCHI KENKYUSHO | 1984-08-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | OR51E2 968/4885PDE4A 4587/4885USP2 615/4885 |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR1, CNR2, OPRD1 | OR51E2 1657/4885PDE4A 4169/4885USP2 2678/4885 |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | CNR2, CNR1, FAAH | OR51E2 3823/4885PDE4A 2022/4885USP2 3402/4885 |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | OR51E2 968/4885PDE4A 4587/4885USP2 615/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | OR51E2 2530/4885PDE4A 2146/4885USP2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.